Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Zhu, Weijun ^a   Jiao, Yanmei ^b   Lei, Rongyue ^a   Hua, Wei ^b   Wang, Rui ^b   Ji, Yunxia ^b   Liu, Zhiying ^b   Wei, Feili ^b   Zhang, Tong ^b   Shi, Xuanlin ^c   Wu, Hao ^b   Zhang, Linqi ^a,c  

^a INSTITUTE OF PATHOGEN BIOLOGY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; VIRUS DNA; CHEMOKINE RECEPTOR CCR5; PRIMER DNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DNA DETERMINATION; DNA SEQUENCE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MOLECULAR DYNAMICS; NONHUMAN; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; BACTERIOPHAGE M13; DRUG EFFECT; GENETICS; HALF LIFE TIME; LONG TERMINAL REPEAT; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; OLIGONUCLEOTIDE PROBE; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIOPHAGE M13; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; DNA PRIMERS; DNA, VIRAL; FEMALE; HALF-LIFE; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE PROBES; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TIME FACTORS; VIRAL LOAD; VIRUS LATENCY; VIRUS REPLICATION; YOUNG ADULT;

EID: 79958173217     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021081     Document Type: Article

References (54)

1. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
3. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191.
4. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
5. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
6. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295.
7. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
8. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15: 893-900.
9. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, et al. (1995) In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1: 1284-1290.
10. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5: 512-517.
11. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9: 727-728.
12. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, et al. (1999) Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 340: 1614-1622.
13. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, et al. (1999) Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 340: 1605-1613.
14. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, et al. (2000) Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 6: 76-81.
15. Strain MC, Gunthard HF, Havlir DV, Ignacio CC, Smith DM, et al. (2003) Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A 100: 4819-4824.
16. Gunthard HF, Frost SD, Leigh-Brown AJ, Ignacio CC, Kee K, et al. (1999) Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 73: 9404-9412.
17. Zhang L, Chung C, Hu BS, He T, Guo Y, et al. (2000) Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 106: 839-845.
18. Chun TW, Davey RT Jr, Engel D, Lane HC, Fauci AS, (1999) Re-emergence of HIV after stopping therapy. Nature 401: 874-875.
19. Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, et al. (2010) Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. Aids 24: 2803-2808.
20. Chun TW, Davey RT Jr, Ostrowski M, Shawn Justement J, Engel D, et al. (2000) Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 6: 757-761.
21. Martinez-Picado J, Frost SD, Izquierdo N, Morales-Lopetegi K, Marfil S, et al. (2002) Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals. J Virol 76: 12344-12348.
22. Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, et al. (2011) Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure. PLoS Pathog 7: e1001303.
23. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, et al. (1990) HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61: 213-222.
24. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, et al. (2008) Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 197: 411-419.
25. Sharkey M, Triques K, Kuritzkes DR, Stevenson M, (2005) In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 79: 5203-5210.
26. Fischer M, Trkola A, Joos B, Hafner R, Joller H, et al. (2003) Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo. Antivir Ther 8: 97-104.
27. Butler SL, Johnson EP, Bushman FD, (2002) Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 76: 3739-3747.
28. Brussel A, Mathez D, Broche-Pierre S, Lancar R, Calvez T, et al. (2003) Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. Aids 17: 645-652.
29. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, et al. (2002) Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 76: 4138-4144.
30. Ibanez A, Puig T, Elias J, Clotet B, Ruiz L, et al. (1999) Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. Aids 13: 1045-1049.
31. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94: 13193-13197.
32. Wong JK, Gunthard HF, Havlir DV, Zhang ZQ, Haase AT, et al. (1997) Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci U S A 94: 12574-12579.
33. Ngo-Giang-Huong N, Deveau C, Da Silva I, Pellegrin I, Venet A, et al. (2001) Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. Aids 15: 665-673.
34. Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, et al. (2004) Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. Aids 18: 45-49.
35. Zanchetta M, Walker S, Burighel N, Bellanova D, Rampon O, et al. (2006) Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy. J Infect Dis 193: 1718-1727.
36. Delaugerre C, Charreau I, Braun J, Nere ML, de Castro N, et al. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. Aids 24: 2391-2395.
37. Yerly S, Perneger TV, Vora S, Hirschel B, Perrin L, (2000) Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. Aids 14: 2805-2812.
38. Sum SS, Wong DK, Yuen MF, Yuan HJ, Yu J, et al. (2004) Real-time PCR assay using molecular beacon for quantitation of hepatitis B virus DNA. J Clin Microbiol 42: 3438-3440.
39. Brussel A, Sonigo P, (2003) Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J Virol 77: 10119-10124.
40. Butler SL, Hansen MS, Bushman FD, (2001) A quantitative assay for HIV DNA integration in vivo. Nat Med 7: 631-634.
41. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, et al. (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2: 1240-1243.
42. Lai JP, Yang JH, Douglas SD, Wang X, Riedel E, et al. (2003) Quantification of CCR5 mRNA in human lymphocytes and macrophages by real-time reverse transcriptase PCR assay. Clin Diagn Lab Immunol 10: 1123-1128.
43. Sachsenberg N, Perelson AS, Yerly S, Schockmel GA, Leduc D, et al. (1998) Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med 187: 1295-1303.
44. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, et al. (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16: 460-465.
45. Gillim-Ross L, Cara A, Klotman ME, (2005) HIV-1 extrachromosomal 2-LTR circular DNA is long-lived in human macrophages. Viral Immunol 18: 190-196.
46. Reigadas S, Andreola ML, Wittkop L, Cosnefroy O, Anies G, et al. (2010) Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. J Antimicrob Chemother 65: 434-437.
47. Andreoni M, Parisi SG, Sarmati L, Nicastri E, Ercoli L, et al. (2000) Cellular proviral HIV-DNA decline and viral isolation in naive subjects with <5000 copies/ml of HIV-RNA and >500×10(6)/l CD4 cells treated with highly active antiretroviral therapy. Aids 14: 23-29.
48. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
49. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, et al. (2008) Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 3: e2516.
50. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, et al. (1998) Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 4: 208-214.
51. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, et al. (1997) Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276: 960-964.
52. Bart PA, Rizzardi GP, Tambussi G, Chave JP, Chapuis AG, et al. (2000) Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. Aids 14: 1887-1897.
53. Beloukas A, Paraskevis D, Haida C, Sypsa V, Hatzakis A, (2009) Development and assessment of a multiplex real-time PCR assay for quantification of human immunodeficiency virus type 1 DNA. J Clin Microbiol 47: 2194-2199.
54. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG, (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882.